Showing 8061-8070 of 10146 results for "".
- ISHRS to Host 32nd World Congress in Denver This Monthhttps://practicaldermatology.com/news/ishrs-host-32nd-world-congress-denver-month/2468370/From refinements in hair restoration surgical techniques to understanding the psychological and physiological aspects of hair loss, the latest research and concepts in hair growth and restoration will be presented by some of the world’s most renowned hair restoration experts when they convene in
- FDA Approves Otezla for Pediatric Psoriasishttps://practicaldermatology.com/news/fda-approves-otezla-for-pediatric-psoriasis-treatment/2468356/Amgen’s Otezla® (apremilast) has been approved by the U.S. Food and Drug Administration (FDA) for pediatric use in treating moderate to severe plaque psoriasis, making it the first oral option for this condition in children. The approval, which to patients ages 6 and older who weigh at lea
- NEA Promotes Eczema Awareness Month in Octoberhttps://practicaldermatology.com/news/nea-promotes-eczema-awareness-month-october/2468331/The National Eczema Association (NEA) will present Eczema Awareness Month throughout October to spread awareness about living with eczema, the organization announced in a press release. This year's awareness campaign puts eczema on display with real, up-close photos of community members' f
- New Photoprotection Data at EADV Congresshttps://practicaldermatology.com/news/new-photoprotection-data-eadv-congress/2468300/Kenvue announced the presentation of two new data sets relating to photoprotection at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will demonstrate "the key to improved skin and hair outcomes through proactive use
- Aerolase Art of Diversity Conference Continues Growinghttps://practicaldermatology.com/news/aerolase-art-diversity-conference-continues-growing/2468263/Aerolase’s third annual Art of Diversity conference in Jersey City, New Jersey, lived up to its name, with a diverse mix of practitioners and content that led to an engaging educational program. “The whole idea of the Art of Diversity for Skin Health is that there is an eclectic community
- Bimekizumab-bkzx Approved for PsA, nr-axSpA, AShttps://practicaldermatology.com/news/bimekizumab-bkzx-approved-psa-nr-axspa/2468260/Bimekizumab-bkzx has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondyl
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- Almirall to Present New Drug Data at EADVhttps://practicaldermatology.com/news/almirall-present-new-drug-data-eadv/2468258/Almirall will present 34 abstracts detailing the latest research on lebrikizumab for moderate-to-severe atopic dermatitis in adolescents and adults and tildrakizumab and Almirall’s CAL/BDP cream for moderate-to-severe plaque psoriasis in adults at the 33rd Congress of the European Academy of Derm
- EADV Presentation to Highlight New IL-13/IL-31 Bispecific Antibodyhttps://practicaldermatology.com/news/eadv-presentation-highlight-new-il-13il-31-bispecific-antibody/2468228/Data from a preclinical study of ZL-1503, an IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Ne
- Organon to Acquire VTAMA Maker Dermavanthttps://practicaldermatology.com/news/organon-acquire-vtama-maker-dermavant/2468226/Organon and Dermavant Sciences Ltd. announced that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant company whose product VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults was approv